Healthscope Limited (HSP) will go ex dividend on 27/9/2010. The current dividend payment is 12 cents and it is 100% franked. The record date is 1/10/2010 and the dividend will be paid on 4/10/2010. Based on the full year payment the dividend yield is 3.8%.
*Current Yield: 2.0% Franking: 100% DRP Discount: 2.5%
*Yield has been calculated on the closing price on the 13/9/2010. Current yield is based on the current dividend payment only.
Healthscope (HSP) announced on the 26/8/2009 that they would be conducting a Share Purchase Plan to raise additional capital. The record date was the 28/8/2009 on which shareholders must own the share to participate in the SPP. The closing date is 1/10/2009. Shares will be issued on 9/10/2009 and begin trading on 13/10/2009. A maximum of $15,000 can be purchased by each shareholder at $4.19.
Discount : 8.3% Liquidity : Good Profitability : Good Stability : Good
* Note: Discount is based on the closing price on the 10 September 2009.
For More Share Purchase Plans go to http://blog.mdsfinancial.com.au/category/share-purchase-plans/
To Buy Shares And Participate in Share Purchase Plans use Trader Dealer http://www.traderdealer.com.au/
Circadian Technologies Limited (CIR) and Healthscope Limited (HSP) announced that they have signed an agreement to commercialise a novel diagnostic technology for so-called “Cancers of Unknown Primaries” – a challenging form of cancer in which the site of origin of a tumour cannot be identified using standard techniques.
The diagnostic method was developed in collaboration between Circadian and the Peter MacCallum Cancer Centre, a leading specialty cancer hospital and research institute in Australia. Under the terms of the agreement, Healthscope, through its subsidiary, Clinical Laboratories Pty Ltd, will further develop, clinically validate and market the test throughout Australia, New Zealand, Malaysia and Singapore. Circadian will retain rights to market the test in the remainder of the world.
Healthscope will pay Circadian an upfront fee, development milestones and a royalty on sales of the test. Circadian, through its wholly owned subsidiary
Cancer Therapeutics Limited, owns exclusive worldwide rights to the test through a licensing arrangement with the Peter MacCallum Cancer Centre.
The Cancers of Unknown Primaries (CUP) diagnostic methodology identifies a patient’s tumour type by comparing its pattern of gene expression to a database of known tumours. By correctly identifying a patient’s tumour type, clinicians can develop a more effective treatment strategy for the cancer.
http://www.healthscope.com.au/info/general/Content/get/228/itemId/
http://www.circadian.com.au/html/s01_home/home.asp
